Guilin Sanjin Pharmaceutical stock dividend – Guilin Sanjin Pharmaceutical Co Ltd Declares 0.4 Cash Dividend

May 26, 2023

Dividends Yield

On May 25, 2023, Guilin Sanjin Pharmaceutical ($SZSE:002275) Co Ltd announced the declaration of a 0.4 CNY cash dividend. Over the past three years, they have consistently issued a dividend per share of 0.9 CNY, 0.9 CNY, and 0.8 CNY respectively, with respective dividend yields of 6.31%, 6.31%, and 5.76%. This gives an average dividend yield of 6.13%. The ex-dividend date for this dividend is May 31, 2023, so make sure to take this into consideration if you are considering investing in Guilin Sanjin Pharmaceutical Co Ltd.

Market Price

This announcement caused the price of its stock to jump 1.6%, with the stock opening at CNY18.6 and closing at CNY18.9 from the previous closing price of 18.6. The company’s board of directors approved the dividend as a part of its long-term strategy to reward investors. This is the second cash dividend in two consecutive years and shows the increasing financial stability of Guilin Sanjin. The company is expected to continue with its dividend policy as it looks to build a strong long-term relationship with its shareholders. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Guilin Sanjin Pharmaceutical. More…

    Total Revenues Net Income Net Margin
    2.16k 378.7 17.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Guilin Sanjin Pharmaceutical. More…

    Operations Investing Financing
    415.14 -75.62 -579.01
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Guilin Sanjin Pharmaceutical. More…

    Total Assets Total Liabilities Book Value Per Share
    4.12k 1.13k 4.79
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Guilin Sanjin Pharmaceutical are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    10.7% 1.5% 24.8%
    FCF Margin ROE ROA
    16.7% 11.5% 8.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Guilin Sanjin Pharmaceutical Intrinsic Value Calculation

    We at GoodWhale have conducted an analysis of GUILIN SANJIN PHARMACEUTICAL’s financials. Based on our proprietary Valuation Line, we have calculated the company’s intrinsic value to be CNY17.2 per share. Currently, GUILIN SANJIN PHARMACEUTICAL stock is being traded at CNY18.9, which is a fair price but is overvalued by 10.1%. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    It faces stiff competition from other companies in the sector such as Biomind Labs Inc, RaQualia Pharma Inc, and Beijing Konruns Pharmaceutical Co Ltd. These companies are all vying for a share of the Chinese pharmaceutical market and are constantly innovating to stay ahead in an increasingly competitive landscape.

    – Biomind Labs Inc ($OTCPK:BMNDF)

    Biomind Labs Inc is a biotechnology company that specializes in the development and commercialization of innovative products for the health and wellness sector. With a market capitalization of 23.11 million USD as of 2023, the company has a prominent presence in the industry and has achieved impressive returns on equity of 374.01%. Its financial performance is indicative of its success in the market and its ability to create value for shareholders. The company has a strong focus on research and development to develop new products that will help to further the mission of improving health and wellness.

    – RaQualia Pharma Inc ($TSE:4579)

    RaQualia Pharma Inc is a leading biopharmaceutical company in Japan that specializes in drug development and commercialization. With a market cap of 17.68B as of 2023, it is well positioned to continue its growth in the sector. Its Return on Equity (ROE) of 8.86% is also an indication of its financial strength and performance within the biopharmaceutical industry. RaQualia Pharma Inc focuses on the development of innovative drugs to treat diseases such as cancer, diabetes, and infectious diseases. The company also offers clinical research services and manufactures and distributes pharmaceutical products to customers in Japan and abroad. RaQualia Pharma Inc has a rich history of success in the biopharmaceutical industry and has been able to consistently deliver strong returns on its investments due to its strong market cap and ROE.

    – Beijing Konruns Pharmaceutical Co Ltd ($SHSE:603590)

    Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company that specializes in developing, manufacturing, and marketing of specialty drugs and other pharmaceutical products. It has a market cap of 6.03B as of 2023 and a Return on Equity of 2.56%. This indicates that the company has the capacity to generate returns by reinvesting its equity rather than distributing it to shareholders. Its market capitalization is an indication of the value of a company’s outstanding shares and is an important indicator of a company’s size and financial health.


    GUILIN SANJIN PHARMACEUTICAL is a dividend stock that is worth considering for investors. Over the last three years, the company has issued an annual dividend per share of 0.9, 0.9, and 0.8 CNY, giving an average dividend yield of 6.13%. This suggests a long-term trend of consistent dividend payout growth, making it an attractive option for income-focused investors. By performing a thorough investment analysis, investors can decide whether this stock is right for their portfolio.

    Recent Posts

    Leave a Comment